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Background and purpose: b-Arrestins are critical scaffold proteins that shape spatiotemporal signalling from seven trans-
membrane domain receptors (7TMRs). Here, we study the association between neuropeptide Y (NPY) receptors and
b-arrestin2, using bimolecular ﬂuorescence complementation (BiFC) to directly report underlying protein–protein interactions.
Experimental approach: Y1 receptors were tagged with a C-terminal fragment, Yc, of yellow ﬂuorescent protein (YFP), and
b-arrestin2 fused with the complementary N-terminal fragment, Yn. After Y receptor–b-arrestin association, YFP fragment
refolding to regenerate ﬂuorescence (BiFC) was examined by confocal microscopy in transfected HEK293 cells. Y receptor/b-
arrestin2 BiFC responses were also quantiﬁed by automated imaging and granularity analysis.
Key results: NPY stimulation promoted association between Y1–Yc and b-arrestin2–Yn, and the speciﬁc development of BiFC
in intracellular compartments, eliminated when using non-interacting receptor and arrestin mutants. Responses developed
irreversibly and were slower than for downstream Y1 receptor–YFP internalization, a consequence of delayed maturation and
stability of complemented YFP. However, b-arrestin2 BiFC measurements delivered appropriate ligand pharmacology for both
Y1 and Y2 receptors, and demonstrated higher afﬁnity of Y1 compared to Y2 receptors for b-arrestin2. Receptor mutagenesis
combined with b-arrestin2 BiFC revealed that alternative arrangements of Ser/Thr residues in the Y1 receptor C tail could
support b-arrestin2 association, and that Y2 receptor–b-arrestin2 interaction was enhanced by the intracellular loop mutation
H155P.
Conclusions and implications: The BiFC approach quantiﬁes Y receptor ligand pharmacology focused on the b-arrestin2
pathway, and provides insight into mechanisms of b-arrestin2 recruitment by activated and phosphorylated 7TMRs, at the level
of protein–protein interaction.
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Abbreviations: 7TMR, seven transmembrane domain receptor; BIBO3304, (R)-N2-(diphenylacetyl)-N-[(4-
(aminocarbonylaminomethyl-)phenyl)methyl]-argininamide; BIBP3226, (R)-N2-(diphenylacetyl)-N-[(4-
hydroxyphenyl)methyl]-argininamide; BiFC, bimolecular ﬂuorescence complementation; BRET or FRET,
bioluminescence or Förster/ﬂuorescence resonance energy transfer; DMEM, Dulbecco’s modiﬁed Eagle’s
medium; ERK, extracellular signal-related kinase; GFP, green ﬂuorescent protein; GR231118 homodimeric,
Ile-Glu-Pro-Dpr-Tyr-Arg-Leu-Arg-Tyr-CONH2;G T P gS, guanosine-5′-O-(3-thio)triphosphate; NPY, neuropeptide
Y; PP, pancreatic polypeptide; PYY, peptide YY; Y1/barr2, stable co-transfected cells expressing FLAG Y1–Yc
and b-arrestin2–Yn; Yc, C-terminal YFP fragment; (c)YFP, (complemented) yellow ﬂuorescent protein; Yn,
N-terminal YFP fragment
Introduction
b-Arrestins are fundamental regulators of seven transmem-
brane domain receptor (7TMR) signalling, co-ordinating tem-
poral and spatial response characteristics. They were
originally identiﬁed as proteins responsible for homologous
desensitization, which bind activated and phosphorylated
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www.brjpharmacol.org7TMRs, and so prevent G protein coupling (Gurevich and
Gurevich, 2006). However, b-arrestins also act as molecular
adaptors to bring many other partners to the 7TMR. For
example, b-arrestins recruit second messenger inactivating
enzymes, such as phosphodiesterase 4D5 (Perry et al., 2002)
or diacylglycerol kinase (Nelson et al., 2007), and association
with clathrin and AP-2 drives 7TMR endocytosis (Gurevich
and Gurevich, 2006). They also scaffold mitogen-activated
protein kinase cascade components, for example, resulting in
cytoplasmic extracellular related kinase (ERK1/2) activity
retained on endosomal 7TMR–b-arrestin complexes (Gurevich
and Gurevich, 2006; Tilley et al., 2009). This diversity in
b-arrestin-mediated events is accompanied by the problem of
its direction by a given ligand–receptor complex, so that sig-
nalling and trafﬁcking can proceed in a speciﬁc manner. This
is particularly pertinent given the potential to develop 7TMR
ligands with biased efﬁcacy towards b-arrestin rather than G
protein-based signalling (Azzi et al., 2003; Baker et al., 2003;
Zidar et al., 2009). Such problems require techniques which
probe the nature of 7TMR association with b-arrestins at the
molecular level, and deliver quantitative pharmacology.
Current methods based on Förster/ﬂuorescence or biolumi-
nescence resonance energy transfer (FRET/BRET) provide this
resolution in living cells (Angers et al., 2000; Berglund et al.,
2003; Charest et al., 2005; Hoffmann et al., 2008; Ouedraogo
et al., 2008), but they can have a limited dynamic range, and
in the case of FRET, the requirement for complex multi-
wavelength analysis.
Bimolecular ﬂuorescence complementation (BiFC) is an
alternative technique for detecting protein–protein associa-
tion in live cells (Kerppola, 2008; Rose et al., 2010). The inves-
tigated proteins are tagged with split N- and C-terminal
fragments of an Aequorea victoria-based ﬂuorescent protein,
such as the yellow variant (YFP). These fragments (Yn, Yc) are
themselves non-ﬂuorescent, but interaction between the
tagged proteins brings Yn and Yc together and promotes their
refolding into the YFP b-barrel structure. Natural maturation
of the chromophore then regenerates YFP ﬂuorescence, giving
a simple single-wavelength signal indicating protein–protein
association (Figure 1). BiFC can be localized at a subcellular
level, and a wide intensity range enhances sensitivity (Kerp-
pola, 2008). Compromises include the slow maturation of
complemented YFP (cYFP), which delays the onset of the BiFC
response, and BiFC complexes also appear irreversible once
formed (Hu et al., 2002). Perhaps because of this, many BiFC
studies have focused on stable interactions, for example,
between transcription factor dimers (Hu et al., 2002), Gbg
subunits (Mervine et al., 2006) or 7TMR dimers (Briddon
et al., 2008; Gandia et al., 2008; Vidi et al., 2008). However,
the ﬁrst fragment refolding step commits a particular interac-
tion to form a BiFC complex, and this is fast enough (half-
time of 60 s in vitro;H uet al., 2002) to trap more transient
associations typical of signalling proteins (Morell et al., 2007).
In the most complete illustration of this possibility, a range of
BiFC-based reporters quantiﬁed the concerted actions of dif-
ferent compounds on various signalling, mitogenic and apo-
ptotic pathways (MacDonald et al., 2006). This study also
conﬁrmed that in principle, the recruitment of b-arrestin2 to
the b2-adrenoceptor could be detected by BiFC reporters (Auld
et al., 2006; MacDonald et al., 2006).
Here, we have assessed a quantitative BiFC approach as a
means to study the association of b-arrestin2 with two typical
rhodopsin-like 7TMRs (Figure 1), the Y1 and Y2 receptors
(nomenclature follows Alexander et al., 2009) for neuropep-
tide Y (NPY) and the related circulating gut hormone peptide
YY (PYY). These receptors are involved in the central control
of appetite, sympathetic vasoconstriction, gut function and
bone development (Michel et al., 1998; Baldock et al., 2007;
Karra et al., 2009). Despite shared Gi/o protein signalling path-
ways (Michel et al., 1998), Y1 receptors associate more efﬁ-
ciently with b-arrestin2 than the Y2 subtype, with a
corresponding inﬂuence on receptor desensitization and
internalization (Berglund et al., 2003; Holliday et al., 2005;
Ouedraogo et al., 2008). Using the BiFC assay, we have
obtained quantitative ligand pharmacology for Y1 receptors
and Y2 receptors focused on the speciﬁc b-arrestin2 signalling
pathway. Moreover, we demonstrate qualitatively distinct
effects of receptor mutations which change the ability of
b-arrestin2 to recognize activated and phosphorylated 7TMRs.
Methods
Molecular biology
Mutations F64L, M153T, V163A and S175G (numbered as
wild-type GFP) were introduced into enhanced YFP cDNA by
QuikChange mutagenesis (Stratagene, La Jolla, CA, USA) to
generatethevenusYFPvariant(Nagaiet al.,2002).Thiswasthe
template for PCR-based construction of Yn and Yc fragments
2–154 (N155) and 2–172 (N173), 155–238 (C155) and 173–238
(C173). Each fragment was placed between XhoI and XbaI
restriction sites in pcDNA3.1zeo+ (Invitrogen, Paisley, UK),
Figure 1 Principle of the 7TMR–b-arrestin2 BiFC assay. Reversible association of b-arrestin2–Yn with NPY-stimulated Y1–Yc receptors promotes
stable Yn and Yc fragment refolding. The formation of the YFP b-barrel allows a slower oxidation reaction to generate the internal
chromophore, resulting in cYFP ﬂuorescence as an indicator of the interaction.
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cDNAs for rat and human Y1 receptors, and the human Y2
receptor, were each PCR ampliﬁed to remove start and stop
codons, and inserted upstream of the ﬂuorescent protein frag-
ments, before transfer to the vector pCMV FLAG (Stratagene).
Receptor fusions were generated which each possessed an
N-terminal FLAG epitope (DYKDDDDK), and were joined at
the C-terminus to YFP or Yc moieties by the linker sequence
LRPLE. FLAG-tagged Y receptor–GFP fusion proteins were con-
structed in the same manner in the pcDNA4/TO vector (Invit-
rogen). Ampliﬁcation of full-length human b-arrestin2 and a
truncated bovine b-arrestin1 fragment (319–418) replaced the
stop codon with a NotI site to allow in frame cloning upstream
of Yn in pcDNA3.1zeo (linker QRPLE). Amino acid substitu-
tions in the Y1 and Y2 receptors were generated by single or
sequential QuikChange mutations. Full sequencing conﬁrmed
the identity of all receptor and arrestin fusion proteins. Primer
sequences are available on request.
Cell culture
HEK293T and 293TR cells (Invitrogen) were cultured in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum and passaged when conﬂuent,
by trypsinization (0.25% w/v in Versene, Lonza, Wokingham,
UK). Transient and stable transfections were performed using
Lipofectamine in Optimem (Invitrogen) according to the
manufacturer’s instructions. Stable HEK293T b-arrestin2–Yn
cell lines were generated by zeocin selection (200 mg·mL
-1)
and dilution cloning, screening positive colonies by deter-
mining the extent of ﬂuorescence complementation follow-
ing b-arrestin2–Yc transfection. Y receptor stable mixed
populations were then established on a common clonal
b-arrestin2–Yn cell background by dual G418 (0.8 mg·mL
-1)
and zeocin resistance. However, the dual cell line expressing
the human Y1 receptor required a second round of dilution
cloning and selection of an individual colony with adequate
receptor expression levels. 293TR Y1–GFP cells were generated
as a blasticidin (5 mg·mL
-1)/zeocin resistant mixed population
after transfection of the pcDNA4/TO Y1–GFP constructs.
These cells, which also express the tetracycline repressor
protein, allowed inducible expression of the Y1 receptor–GFP
fusion protein after tetracycline treatment (1 mg·mL
-1,
18–21 h before experiments). Stable transfected cell lines were
maintained in low levels of blasticidin (5 mg·mL
-1), zeocin
(50 mg·mL
-1) or G418 (0.1 mg·mL
-1) as appropriate to ensure
continued selection pressure.
[
125I]PYY binding experiments
Membranes were freshly prepared from Y receptor cell lines by
two cycles of cold homogenization and centrifugation at
40 000¥ g, resuspending the pellet in 25 mM HEPES, 1 mM
Na2EDTA and 0.1 mM 4-(2-aminoethyl) benzenesulphonyl
ﬂuoride (pH 7.4). Protein content was determined by Pierce
bicinchoninic acid assay (Fisher, Loughborough, UK). Com-
petition binding assays were performed for 2 h at 21°C in
buffer (25 mM HEPES, 2.5 mM CaCl2, 1.0 mM MgCl2, 0.1%
bovine serum albumin, 0.1 mg·mL
-1 bacitracin; pH 7.4) and
increasing concentrations of unlabelled ligands (0.1 pM–
1 mM, duplicate), using appropriate radioligand conditions for
Y1 receptors (15 pM [
125I]PYY, 20–40 ng·mL
-1 membrane
protein) or the Y2 subtype (10 pM [
125I]PYY, 2–4 ng·mL
-1 mem-
brane protein). GTPgS displacements also included 30 mg·mL
-1
saponin in the assay buffer. Membrane-bound radioligand
was separated by ﬁltration through Whatman GF/B ﬁlters
soaked in 0.3% polyethyleneimine on a Brandel cell harvester
(Alpha Biotech, London, UK), and retained radioactivity was
quantiﬁed using a gamma-counter (Packard Cobra II, Perki-
nElmer, Waltham, MA, USA). Non-speciﬁc binding in these
experiments comprised less than 5% of total counts.
Confocal microscopy
HEK293T cells were seeded overnight onto 25 mm poly-L-
lysine-coated coverslips, and transiently co-transfected with
Y1 receptor/b-arrestin cDNAs. Twenty-four hours later, surface
Y1 receptors were live labelled with the M2 anti-FLAG anti-
body as previously described (Holliday et al., 2005) prior to
stimulation with vehicle or 1 mM NPY for 60 min. Incubations
were terminated by ﬁxation, the cells were permeabilized with
0.075% Triton X-100 and the bound M2 antibody was iden-
tiﬁed by a goat anti-mouse secondary antibody conjugated to
Rhodamine Red X. For live studies, cells were grown for 24 h
in eight-well Nunc Labtek chamber slides coated with poly-L-
lysine (Fisher, Loughborough, UK), and incubated during
imaging in Hank’s balanced salt solution (with 0.1% bovine
serum albumin) in the presence or absence of 1 mM NPY.
Confocal images were acquired on a Zeiss LSM 510 laser
scanning microscope L87, C2 (Carl Zeiss, Ltd., Welwyn, UK)
using a 63¥ Plan-Apochromat NA 1.4 oil objective, and Ar
488 nm (GFP/YFP) or HeNe 543 nm (Rhodamine Red X) laser
lines for excitation. Dual labelled samples were collected in
separate scans with emission ﬁlters for 505/550 nm band pass
(GFP/YFP), together with long pass 560 nm (Rhodamine Red
X) and a pinhole diameter of 1 Airy unit set for the longer
wavelength. Equivalent laser power and gain settings were
used for images of control and agonist-treated cells within the
same experiment. Identical linear adjustments to contrast and
brightness were made to representative images in the ﬁgures
for presentation purposes.
Automated imaging of Y receptor–arrestin BiFC responses and Y1
receptor internalization
Dual stable Y receptor/b-arrestin2 BiFC clones, or Y1–YFP
cells, were seeded at 50 000 cells per well onto poly-L-lysine-
coated 96-well black clear-bottom plates (Costar 3904, Fisher).
The next day, the medium was replaced with DMEM/0.1%
bovine serum albumin in the presence or absence of antago-
nist ligands (30 min, 37°C). Agonists were then added for the
times indicated (0.1 nM–3 mM, triplicate wells) before incuba-
tions were terminated by ﬁxation with 3% paraformaldehyde
in phosphate-buffered saline (PBS, 10 min at 21°C). After two
PBS washes, cell nuclei were stained for 5 min with the per-
meable dye H33342 (1 mg·mL
-1 in PBS, Sigma, Poole, UK) and
rinsed in PBS. Images (four central sites per well) were
acquired automatically on an IX Ultra confocal plate reader
(Molecular Devices, Sunnyvale, CA, USA), equipped with a
Plan Fluor 40¥ NA0.6 extra-long working distance objective
and 405/488 nm laser lines for H33342 and cYFP excitation
respectively. Negative and positive controls (vehicle, 1 mM
BiFC measures NPY receptor–b-arrestin interaction
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malization; for mutational studies, these controls were pro-
vided by the dual cell line expressing the relevant native Y
receptor.
Data analysis
YFP ﬂuorescent images acquired on the IX Ultra were analy-
sed by a granularity algorithm (Transﬂor, Metaexpress 2.0,
Molecular Devices) which identiﬁed compartments of at least
3 mm diameter (range set to 3–18 mm, ‘vesicles’). Simultaneous
classiﬁcation of smaller compartments (1–3 mm ‘pits’) pro-
vided a data set with equivalent results which, for simplicity,
is not shown here. In a given experiment, intensity thresholds
for granule classiﬁcation were set with reference to the nega-
tive and positive plate controls. When combined with the
nuclear count obtained from the paired H33342 image,
granularity analysis provided parameters of vesicle count, area
and average intensity per cell, in which each individual data
point was obtained from assessment of 12 images (four sites
per well in triplicate). Concentration–response curves for dif-
ferent ligands were then normalized as a percentage of the
control response (typically 1 mM NPY for the respective native
Y receptor), and this allowed pooling of individual experi-
ments. Curves were ﬁtted to the pooled data by non-linear
least square regression, and where appropriate multiple com-
parisons between data groups were assessed for signiﬁcance by
one-way ANOVA and Dunnett’s post-test (Graphpad Prism
v5.01, San Diego, CA, USA).
Binding pKi values were estimated from IC50 measurements
in [
125I]PYY competition studies using the Cheng–Prusoff
equation. Due to the relatively low levels of receptor expres-
sion in Y receptor/b-arrestin2 clones, Bmax estimates were
obtained from homologous PYY displacements according to
the equation Bmax = TSB ¥ IC50/[L], where TSB is the total
speciﬁc binding in the absence of agonist, and [L] is the
radioligand concentration.
Materials
The enhanced YFP cDNA sequence was kindly provided by Dr
F. Ciruela (University of Barcelona, Barcelona, Spain). Molecu-
lar biology reagents were purchased from Fermentas (St.Leon-
Rot, Germany), Promega (Southampton, UK) or Sigma (Poole,
UK). The M2 monoclonal anti-FLAG antibody and secondary
antibody conjugates were from Sigma and Invitrogen respec-
tively. [
125I]PYY (speciﬁc activity 81.4 TBq mmol
-1) was pro-
vided by PerkinElmer. All non-labelled peptides were
purchased from Bachem (St. Helens, UK) and stored as single-
use aliquots at -20°C. BIBP3226 was obtained from Sigma,
while BIBO3304 was a gift from Boehringer-Ingelheim, GmbH
(Biberach, Germany). Cell culture media and selection anti-
biotics were sourced from Sigma, Lonza (Wokingham, UK) or
Invitrogen as appropriate.
Results
NPY Y1 receptor association with b-arrestin2 can be detected
by BiFC
We used BiFC fragment pairs based on a rapid folding YFP
variant called venus (Nagai et al., 2002), to maximize trapping
of agonist-induced Y1 receptor–b-arrestin2 complexes at
physiological temperature (37°C). Early optimization sug-
gested that C-terminal tagging of the rat Y1 receptor with Yc
(155–238) was most suitable, in combination with b-arrestin2
fused at the C-terminus to Yn (1–173). This overlapping pair
(N173:C155) repeats a b-strand (155–172) in both Yn and Yc,
as an aid to the refolding process (Hu and Kerppola, 2003).
Y1–Yc and barr2–Yn cDNAs were co-transfected into HEK293
cells, and receptors were identiﬁed by live antibody labelling
of the N-terminal FLAG epitope (Figure 2). Under control
conditions, relatively low levels of cYFP ﬂuorescence were
observed, but following 60 min treatment with NPY, there
was a marked increase in BiFC. This was located principally
in perinuclear intracellular compartments and largely
co-localized with receptor immunoreactivity. In contrast, the
agonist-induced BiFC response was absent when using a trun-
cated Y1 receptor construct lacking much of the C-terminal
tail after the palmitoylation site (DY346), or when full-length
Y1–Yc was partnered with truncated b-arr1(318–419)–Yn
without receptor binding domains (Figure 2). In both these
controls, Y1 receptor internalization was also largely
prevented.
We derived more quantitative data on the BiFC response by
obtaining dual stable clones with Y1–Yc receptors as a mixed
population ([
125I] PYY Bmax 350  60 fmol·mg
-1 membrane
protein; n = 4) established on a barr2–Yn clonal cell line,
called Y1/barr2. The majority of Y1/barr2 cells responded to
NPY stimulation with increased vesicular cYFP ﬂuorescence
(see Supporting Information Figure S1). When seeded into
96-well plates, images from these cells could be collected in an
automated manner using a confocal plate reader (Figure 3). A
granularity algorithm identiﬁed the larger BiFC-positive com-
partments (‘vesicles’, >3 mm diameter) within every image,
and calculated various vesicle parameters normalized to the
nuclear count. This unbiased analysis enabled derivation of
full ligand concentration–response curves for each parameter,
and the calculation of NPY pEC50 values (range: 8.51–8.70) for
the stimulation of Y1/barr2 BiFC (Figure 3). In subsequent
experiments, vesicle count and area measurements produced
similar results to data based on vesicle average intensity,
which is presented here.
Kinetics and reversibility of Y1/barr2 BiFC
cYFP localization patterns observed in Y1/barr2 cells were
similar under control or NPY-treated conditions, with pre-
dominant (although not exclusive) intracellular distribution
in perinuclear compartments. Thus, the increased vesicular
cYFP intensity after agonist stimulation strongly indicated the
generation of de novo BiFC, rather than trafﬁcking of pre-
existing complexes. In order to exclude this second possibility
entirely, NPY responses in Y1/b-arr2 cells were compared to
the time-proﬁles of NPY-stimulated Y1 receptor trafﬁcking
(Figure 4). Endocytosis assays used HEK293 cells stably trans-
fected with Y1 receptors fused to full-length venus YFP. The
granularity algorithm was applied to plate reader Y1–YFP
images to detect and quantify internalized receptors (see Sup-
porting Information Figure S2), using the same vesicle diam-
eter constraints applied to BiFC images.
Development of Y1/b-arr2 BiFC in response to 100 nM NPY
(t1/2 10.4  1.0 min, n = 3; Figure 4B) was signiﬁcantly slower
BiFC measures NPY receptor–b-arrestin interaction
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0.3 min, n = 3; P < 0.05; Figure 4A). Agonist removal by three
washes with medium, lasting 1 h in total, led to complete
recovery of the Y1–YFP receptor at the cell surface, and asso-
ciated reversibility of the ﬂuorescence signal in endocytic
compartments (Figure 4A; NPY response after washing: 8.3 
11.7% (n = 3) of control 2 h NPY response). In contrast,
Figure 4B shows that NPY-stimulated Y1/b-arr2 BiFC persisted
after the same wash protocol (75.4  12.0% of control 2 h
NPY response, n = 3; P < 0.05 compared to Y1–YFP data).
We also considered the effect of using different BiFC frag-
ment pairs on NPY response kinetics (Figure 4C,D). Y1/b-arr2
cells, using the overlapping N173:C155 combination, were
compared with two alternative dual clones. These expressed
either Y1–Yc (155–238) paired with barr2–Yn (1–154)
(N155:C155, [
125I] PYY Bmax 650  100 fmol·mg
-1 membrane
protein, n = 4) or Y1–Yc (173–238) in combination with
barr2–Yn (1–172) (N173:C173; [
125I] PYY Bmax 300 
120 fmol·mg
-1 membrane protein, n = 3). Both exhibited
slower BiFC responses to 100 nM NPY (N155:C155 t1/2 17.5 
2.6 min, n = 4; N173:C173 t1/2 20.9  1.7 min, n = 3; both P <
0.05 compared to Y1/barr2 cells, N173:C155). However, as for
Y1/barr2 cells (N173:C155), the NPY-induced BiFC in each
case was largely irreversible (Figure 4C,D).
Agonist and antagonist pharmacology
NPY concentration–response curves measured in Y1/barr2
cells yielded similar potency estimates when incubation times
were varied from 15 min to 4 h (pEC50 range: 8.39–8.60; n =
3); however, the maximum agonist-induced BiFC response
was greatest following incubation times of 1 h or greater.
Using 1 h incubation times, comparison of different peptide
agonists demonstrated typical Y1 receptor pharmacology for
stimulation of Y1/barr2 BiFC. The endogenous ligands NPY
and PYY, and the selective analogue [Leu
31, Pro
34]NPY were
equipotent full agonists (Figure 5). In contrast, the third NPY
family member, pancreatic polypeptide (PP), and the metabo-
lite NPY3–36 were much less potent. Both the rank order of
potency and the actual pEC50 values obtained were similar to
those measured for stimulation of Y1–YFP endocytosis
(Figure 5; Table 1). Moreover, concentration–response curves
to the different agonists were not inﬂuenced by the use of
alternative YFP fragment pairs to generate Y1/barr2 BiFC
(Figure 5; Table 1).
A peptide Y1 receptor antagonist GR231118, reported to
increase Y1 receptor internalization (Pheng et al., 2003), was
inactive in both Y1–YFP endocytosis and barr2 BiFC assays
(Figure 5). Equally, Y1/barr2 BiFC was not altered by the non-
peptide antagonists BIBP3226 (1 mM yielded -4.5  10.0% of
1 mM NPY response; n = 4) or BIBO3304 (at 30 nM: -8.7 
7.5% of 1 mM NPY response; n = 5). However, 30 min pre-
incubation with either BIBP3226 or BIBO3304 resulted in
parallel rightward shifts of the NPY concentration–response
curves for Y1/barr2 BiFC, consistent with competitive revers-
ible antagonism (Figure 6). The respective Schild plots yielded
pA2 estimates of 8.0  0.1 for BIBP3226 (slope 1.1  0.1, n =
4) and 9.0  0.1 for BIBO3304 (slope 1.1  0.1, n = 5). This
functional estimate for BIBO3304 afﬁnity was the same as its
pKi measured in [
125I]PYY competition assays in Y1/barr2
membranes (Table 2). GR231118 also acted as an antagonist
in similar pre-incubation experiments (Figure 6C), yielding a
pA2 estimate of 8.6  0.2 (n = 4); however, linear GR231118
Schild plots were greater than unity (slope 1.5  0.2).
Stable expression of the human Y1 receptor is more difﬁcult
than for its rat orthologue, but we were also able to derive a
Figure 2 NPY speciﬁcally stimulates Y1 receptor–b-arrestin2 BiFC. HEK293 cells were transiently co-transfected with FLAG-tagged Y1
receptor–Yc and b-arrestin–Yn plasmids. Cells were live labelled 24 h later with M2 anti-FLAG antibody before treatment with vehicle or 1 mM
NPY for 60 min at 37°C. Following ﬁxation, the M2 antibody was identiﬁed in ﬁxed cells by a secondary antibody conjugated to Rhodamine
Red X. Images were acquired using a Zeiss LSM510 confocal microscope with laser excitation at 488 nm (cYFP BiFC ﬂuorescence, and phase)
or 543 nm (M2 detected FLAG Y1 receptors). Representative images are shown from one of at least three experiments. They illustrate the
increase in BiFC ﬂuorescence, co-localized with receptor immunoreactivity, in NPY-stimulated cells co-transfected with Y1–Yc and b-arrestin2–
Yn. This response was absent when using either a Y1 receptor–Yc construct lacking the C tail after Tyr346 (DY346), or a dominant negative
(DN) truncated b-arrestin1(319–418)–Yn.
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of the human Y1 receptor with b-arrestin2 by BiFC ([
125I]PYY
Bmax: 610  20 fmol·mg
-1, n = 3). This demonstrated equiva-
lent agonist and BIBO3304 pharmacology for both rat and
human Y1 receptor/barr2 association (Figure 7).
Mutational analysis of Y1 receptor/b-arrestin2 interaction
We examined whether the BiFC assay could quantify the
effects of receptor mutation on b-arrestin2 recruitment.
Y1/barr2 responses were compared with those in clones
expressing Y1–Yc mutant receptors as a mixed population on
the same barr2–Yn parent cell line. For each experiment,
Y1/barr2 cell controls on the same plate ensured appropriate
normalization of the data, and no change in overall subcel-
lular distribution of cYFP complexes was evident with any
receptor mutant. We ﬁrst investigated the effect of Y99A sub-
stitution, which prevents NPY binding to the Y1 receptor
(Sjodin et al., 2006), and the C tail truncation DY346 which
prevented barr2 BiFC in transiently transfected cells
(Figure 2). Receptor expression was detected by anti-FLAG
labelling in both Y1Y99A/barr2 and Y1DY346/barr2 cells (data
not shown), and by [
125I]PYY binding experiments in the
Y1DY346/barr2 clone (Table 2). However, both mutations
eliminated NPY stimulated BiFC responses measured by
granularity analysis (Table 3).
Previous work by our own and other groups has identiﬁed a
phosphorylated sequence in the Y1 receptor C-terminus
(serine 352–serine 362) which is implicated in b-arrestin
binding and its functional consequences, such as desensitiza-
tion of G protein coupling and receptor internalization (Hol-
liday et al., 2005; Ouedraogo et al., 2008). We assessed the
relative importance of the six serine/threonine residues
within this region by their mutation to alanine, alone or in
combination (Figure 8). Mutant Y1 receptors were expressed
at a similar level to Y1–Yc in dual barr2 clones, and displayed
Figure 3 Quantitative analysis of Y1 receptor–b-arrestin2 BiFC. Example images acquired on an IX Ultra plate reader (A) show stable
co-transfected Y1/barr2 cells under control conditions or treated with 1 mM NPY for 60 min (see also Supporting Information Figure S1 for
higher resolution). Images of H33342 nuclei staining (left panels) and b-arrestin2 BiFC ﬂuorescence (central panels) were processed by a
granularity algorithm with results shown in the right-hand panels. The analysis identiﬁed nuclei in green, and BiFC compartments more than
3 mm in diameter (white dots) based on detection thresholds set with reference to the plate controls. In (B), pooled data from the granularity
analysis are presented as normalized NPY concentration–response curves (n = 10) for vesicle count/cell (pEC50 8.70  0.09), vesicle area/cell
(pEC50 8.51  0.06) and vesicle average intensity/cell (pEC50 8.57  0.05).
BiFC measures NPY receptor–b-arrestin interaction
LE Kilpatrick et al 897
British Journal of Pharmacology (2010) 160 892–906BiFC measures NPY receptor–b-arrestin interaction
898 LE Kilpatrick et al
British Journal of Pharmacology (2010) 160 892–906equivalent agonist and antagonist binding afﬁnities in
[
125I]PYY competition assays. In each case, [
125I]PYY binding
was also sensitive to GTPgS, an indicator of appropriate G
protein coupling (Table 2).
Paired substitution of S352A, T353A (STA) or T356A mod-
estly reduced maximal NPY- and PYY-stimulated Y1/barr2
BiFC. S359A or the double mutant T361A, S362A (TSA) were
individually without effect, but these mutations did signiﬁ-
cantly enhance the inhibition afforded by either STA or
T356A (Figure 8; Table 3). Combinations eliminating 4/6 Ser/
Thr residues inhibited maximal agonist-stimulated BiFC by
55–65%, despite preserving T356 in the sequence (STA, TSA
mutant) or S352 and T353 (T356A, S359A, TSA mutant).
Agonist responses were almost entirely eliminated by muta-
tion of the remaining two serine or threonine residues, either
in the Y1 5A mutant (with only T356 still present) or in the Y1
6A construct (Figure 7; Table 3). No phosphorylation site
mutation altered the potencies of NPY or PYY BiFC responses,
when these could be accurately measured (Figure 8; Table 3).
The 6A mutation was also sufﬁcient to prevent agonist-
stimulated Y1 receptor internalization (Figure 9). For
example, stimulation of Y1–GFP receptors by NPY (1 mM) led
to rapid receptor internalization, while Y16A–GFP receptors
did not undergo endocytosis with the same treatment.
Figure 4 Kinetics and reversibility of b-arrestin2 BiFC compared to Y1–YFP internalization. Y1–YFP endocytosis was measured in HEK293 cells
using the granularity algorithm (A, see also example in Supporting Information Figure S2). This was compared to the quantiﬁed BiFC responses
in Y1/barr2 cells using the N173:C155 fragment pair (B), or alternative stable clones expressing (C) Y1–Yc (155–238) and b-arrestin2–Yn (1–154)
(N155:C155) or (D) Y1–Yc (173–238) and b-arrestin2–Yn (1–172) (N173:C173). Single example experiments (from n = 3) show a 2 h
time-course for vehicle or 100 nM NPY treatment, in which cells were ﬁxed immediately (left-hand graphs, control), or the agonist ﬁrst removed
by three media washes (for 60 min at 37°C, right-hand graphs). Control NPY time-courses were ﬁtted with a one-phase hyperbola which gave
individual half-times (t1/2) of 1.8 min (A, Y1–YFP), 8.7 min (B, N173:C155), 11.5 min (C, N155:C155) and 13.4 min (D, N173:C173). For
comparison, these ﬁts are represented as dotted lines on the right-hand graphs. Pooled t1/2 measurements are given in the text.

Figure 5 Concentration–response curves for Y1–YFP receptor internalization and Y1 receptor–b-arrestin2 BiFC. Responses to different ligands
were measured by granularity analysis applied to automated plate reader images (calculating vesicle average intensity/cell), and normalized
to the positive control on each plate (1 mM NPY). Combined data from stably transfected cells are presented for Y1–YFP internalization
following 15 min treatment (A, n = 3–5), or Y1 receptor–b-arrestin2 BiFC measured at 60 min, using Yn and Yc partners N173:C155 (B, n =
4–10), N155: C155 (C, n = 4–6) or N173:C173 (D, n = 2–6). Peptides examined included [Leu
31, Pro34]NPY (ProNPY) and GR231118 (GR, A
and B only). Where appropriate, pEC50 values from the pooled data are presented in Table 1.
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Agonist Y1–YFP internalization Y1/barr2 N173:C155 Y1/barr2 N155:C155 Y1/barr2 N173:C173
pEC50 1 mM (%) pEC50 1 mM (%) pEC50 1 mM (%) pEC50 1 mM (%)
NPY 8.85  0.07 100 8.57  0.05 100 8.52  0.04 100 8.73  0.09 100
PYY 8.81  0.10 96.6  2.3 8.54  0.06 98.6  7.6 8.47  0.05 101.6  8.5 8.74  0.08 90.3  22.0
ProNPY 8.18  0.08 90.1  7.6 8.43  0.08 93.4  3.1 8.24  0.06 93.5  4.5 8.41  0.10 95.3  10.5
NPY3–36 <7.0 61.8  10.8 <7.0 65.0  13.0 <7.0 69.5  4.0 <7.0 61.6  4.1
PP <7.0 59.9  8.9 <7.0 54.7  3.4 <7.0 52.1  5.3 <7.0 31.6
pEC50 data were obtained from concentration–response curves presented in Figure 5 (n = 2–10). N173:C155, N155:C155 and N173:C173 indicate the speciﬁc Yn
and Yc partners used to generate BiFC responses for each Y1/barr2 cell line; 1 mM responses to each ligand were expressed as a percentage of the NPY response.
ProNPY, [Leu31,P r o 34]NPY.
Figure 6 Antagonists inhibit Y1 receptor–b-arrestin2 BiFC. In the example, triplicate experiments shown, Y1/barr2 cells were pretreated for
30 min with antagonists BIBP3226 (A), BIBO3304 (B) and GR231118 (C) at the concentrations indicated. NPY was then applied for 60 min,
before measuring BiFC responses (vesicle average intensity/cell, normalized to control 1 mM NPY in each case). NPY concentration–response
curves in the absence or presence of antagonist were ﬁtted (GraphPad Prism) assuming shared minimum, maximum and Hill slope constants.
The EC50 concentration ratios (CR) were used to construct Schild plots with the following ﬁts for BIBP3326 (pA2 7.8, slope 1.1), BIBO3304 (pA2
9.1, slope 1.0) and GR231118 (pA2 8.3, slope 1.9). Pooled pA2 values are given in the text.
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BiFC assay
Finally, we studied whether BiFC measurement of b-arrestin2
association could be applied to the human Y2 receptor, a
subtype that also binds NPY and PYY, but is reported to recruit
b-arrestin2 much less efﬁciently (Berglund et al., 2003; Marion
et al., 2006). Receptor expression levels were slightly higher in
the Y2–Yc/barr2–Yn clone compared to Y1/barr2 cells, with
increased afﬁnity for PYY (Table 2). Nevertheless, NPY, and to
a lesser extent PYY, were signiﬁcantly less potent agonists for
stimulating Y2/barr2 BiFC (Figure 10; Table 3) than observed
for Y1/barr2 responses (19-fold difference comparing NPY
EC50 values; P < 0.001). In Y2/barr2 cells, [Leu
31, Pro
34]NPY was
inactive (up to 1 mM) while the C-terminal fragment PYY3–36
was a full agonist as potent as PYY (pEC50 7.71  0.10, n = 4).
H155P substitution in the Y2 receptor second intracellular
loop has been reported to increase receptor afﬁnity for
b-arrestin2 (Marion et al., 2006). Despite equivalent levels of
receptor expression (Table 2), Y2H155P/barr2 cells exhibited
signiﬁcantly increased basal and agonist-stimulated BiFC
responses (Figure 10B). This was accompanied by a marked
increase in potency for the agonists NPY and PYY (pEC50si n
Table 3), and for PYY3–36 (pEC50 8.60  0.22, n = 4).
Discussion
Here, we have described the use of BiFC to report the direct
molecular association between typical 7TMRs (the Y1 or Y2
NPY receptors) and b-arrestin2. We used automated image
analysis to quantify BiFC ﬂuorescence readouts within indi-
vidual cells in an unbiased manner, although other methods
are also possible (Morell et al., 2007). As for all 7TMR–b-
arrestin assays, there were both advantages and limitations to
the BiFC technique. However, the BiFC assay was able to
provide quantitative ligand pharmacology and insight into
Table 2 Summary of binding parameters for Y1 and Y2/barr2 dual clones
Receptor PYY BIBO3304 GTPgS
pKi Bmax (fmol·mg
-1)p Ki pIC50 1 mM inhibition (%)
Y1 9.76  0.10 350  60 9.01  0.12 9.05  0.21 58.6  4.1
Y1 DY346 9.59  0.12 980  200 9.03  0.04 8.57  0.04 61.9  8.8
Y1 STA 9.76  0.03 420  70 9.05  0.06 9.00  0.15 61.4  4.0
Y1 T356A 9.65  0.14 570  120 9.08  0.09 8.97  0.17 48.3  4.7
Y1 S359A 9.74  0.08 580  110 9.06  0.08 9.18  0.08 54.7  3.5
Y1 TSA 9.73  0.07 580  20 9.25  0.25 9.40  0.10 51.4  4.9
Y1 STA, TSA 9.77  0.08 580  170 9.01  0.07 9.03  0.26 58.2  5.0
Y1 T356A, S359A, TSA 9.71  0.08 500  100 8.98  0.06 9.21  0.20 53.0  7.4
Y1 5A 9.60  0.06 440  50 9.01  0.15 8.81  0.28 55.7  3.4
Y1 6A 9.63  0.02 340  30 9.14  0.22 9.04  0.02 63.2  1.2
Y2 11.10  0.13 1190  120 Not tested 9.19  0.11 73.8  3.5
Y2 H155P 11.03  0.08 1440  300 Not tested 9.17  0.05 70.2  5.3
All parameters were obtained from [125I]PYY competition experiments as described in the Methods. In each case, maximal inhibition of [125I]PYY speciﬁc binding
was afforded by 1 mM GTPgS. Details of the various Y1 receptor mutations are given in the text.
Figure 7 Agonist and antagonist data for human Y1 receptor stimulated b-arrestin2 BiFC. Human hY1/barr2 cells were derived after further
dilution cloning to optimize receptor and arrestin construct expression. The similarity with rat Y1/barr2 cell data is illustrated by agonist
concentration–response curves in (A), for 60 min treatment with NPY (pEC50: 8.99  0.08, n = 7), PYY (pEC50: 8.76  0.09, n = 6 ) ,P P( n =
6), [Leu31,P r o 34]NPY (ProNPY pEC50: 8.65  0.06, n = 7) and NPY3–36 (n = 6). In (B), 30 min pre-incubation with 10 nM BIBO3304 (BIBO)
resulted in a 9.1-fold rightward shift in the NPY concentration–response relationship (n = 5) from which a pKB of 8.9 was calculated.
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by NPY receptors. It distinguished Y receptor mutations pre-
dicted to alter recognition by b-arrestin activation or phos-
phorylation sensors. Moreover, it indicated that alternative
arrangements of Ser/Thr residues in the Y1 receptor C tail can
support b-arrestin2 association.
Current popular imaging methods use FRET/BRET to
measure 7TMR–b-arrestin interactions (Angers et al., 2000;
Berglund et al., 2003; Charest et al., 2005; Hoffmann et al.,
2008). RET assays report real-time responses as soon as the
proximity or orientation of the donor and acceptor ﬂuoro-
phores changes. However, the generation of BiFC requires a
sufﬁciently sustained protein–protein interaction to allow Yn
and Yc fragment refolding to take place, although the dis-
tance constraints for complementation appear similar to RET
(<10 nm apart; Remy et al., 1999). Overlapping fragments
from venus YFP (Nagai et al., 2002; Hu and Kerppola, 2003;
MacDonald et al., 2006) maximized refolding rates, and were
successful in trapping acute Y receptor–b-arrestin2 recruit-
ment. Lower incubation temperatures were also unnecessary,
in contrast to BiFC experiments with standard YFP constructs
(Hu et al., 2002; Briddon et al., 2008). The disadvantage of
using rapidly refolding BiFC partners can be elevated self-
association and background signal (Kerppola, 2008). Multiple
negative controls using Y1 receptor or b-arrestin mutants
demonstrated that the non-speciﬁc BiFC response was low.
Clearly, speciﬁcity is aided by compartmentalization of cell
surface receptors and cytoplasmic b-arrestin2 until a stimulus
brings them together. As Yn/Yc refolding is not instanta-
neous, it also reduces inappropriate BiFC signals from non-
speciﬁc ‘bystander’ interactions.
A granularity algorithm applied to confocal plate reader
images measured the intensity of Y receptor–b-arrestin2 BiFC
in perinuclear compartments of stable co-transfected cells.
This demonstrated ﬁrst that NPY-induced BiFC developed
with slow irreversible kinetics. The contrast with more rapid
and reversible Y1–YFP receptor internalization, itself a
b-arrestin-mediated event (Holliday et al., 2005; Ouedraogo
et al., 2008), provided convincing evidence that NPY stimu-
lation formed new BiFC complexes, rather than altering the
trafﬁcking of pre-existing ones. Thus, the BiFC assay is not a
real-time indicator of b-arrestin2 recruitment. Fast refolding
commits the complex to produce a ﬂuorescent signal
(Figure 1), but detection is artiﬁcially delayed by slow cYFP
maturation (half-time ~50 min in vitro;H uet al., 2002). Con-
ceivably, this process could inﬂuence agonist potency, for
example, if the afﬁnities of Yn and Yc for each other made a
contribution to Y receptor–b-arrestin2 binding. Different lines
of evidence demonstrate that this is not the case. First, NPY
potencies did not change with incubation time, suggesting
that longer stimulation increased only the proportion of
refolded cYFP that matured and became ﬂuorescent. Com-
parison of different peptide agonists, including Pro
34 substi-
tuted analogues and 3–36 fragments (Michel et al., 1998),
provided the expected orders of potencies for Y1 or Y2
receptor-stimulated b-arrestin2 BiFC. For Y1 receptor
responses, there was also a close correspondence with equiva-
lent measurements for a dependent process, namely Y1–YFP
internalization. The lower b-arrestin2 afﬁnity of Y2 compared
to Y1 receptors, originally evident from BRET measurements
(Berglund et al., 2003), was maintained in the BiFC assay.
Most signiﬁcantly, the afﬁnities of Yn and Yc for each other
could be adjusted by using different BiFC pairs, but this choice
only inﬂuenced the kinetics of the Y1 receptor–b-arrestin2
response, and not agonist potency. We conclude that the BiFC
approach provides reliable potency estimates for agonist-
stimulated b-arrestin2 recruitment by Y receptors.
Our data support the consensus that in reforming the stable
YFP b-barrel structure, BiFC generates an irreversible complex
(Hu et al., 2002; Morell et al., 2007; Kerppola, 2008). This has
practical advantages in comparison to RET methods, in that
the response is sustained and less dependent on the time of
measurement. However, the stability of 7TMR–b-arrestin com-
plexes, as well as initial association, is functionally important
(Gurevich and Gurevich, 2006; Tilley et al., 2009). The life-
time of b-arrestin interaction can depend on the 7TMR inves-
Table 3 Effect of Y1 and Y2 mutations on agonist potency and maximum response in the b-arrestin2 BiFC assay
Receptor NPY PYY
pEC50 1 mM response pEC50 1 mM response
Y1 8.57  0.05 100 8.54  0.06 98.6  7.6
Y1 Y99A – 13.0  3.6*** Not tested Not tested
Y1 DY346 – 13.4  4.7*** Not tested Not tested
Y1 STA 8.49  0.12 58.1  5.7*** 8.60  0.16 77.6  4.2
Y1 T356A 8.81  0.22 60.2  4.7*** 8.69  0.19 67.9  6.2*
Y1 S359A 8.56  0.16 77.9  8.8 8.45  0.16 74.1  13.4
Y1 TSA 8.59  0.16 79.8  10.8 8.76  0.16 77.4  7.8
Y1 STA, TSA 8.41  0.23 34.8  7.1*** 8.58  0.42 46.5  5.5***
Y1 T356A, S359A, TSA 8.53  0.18 34.3  11.2*** 8.34  0.32 33.0  9.5***
Y1 5A – 14.2  3.1*** – 8.7  3.8***
Y1 6A – 19.7  14.2*** – 9.5  13.5***
Y2 7.15  0.08 100 7.82  0.09 101.8  3.3
Y2 H155P 8.05  0.34* 175.9  29.2* 8.79  0.28* 168.2  23.9*
Data are obtained from 4–10 experiments (see also concentration–response curves in Figures 8 and 10). pEC50s are not quoted (–) in mutants where agonist
responses were too small for accurate estimates. Some mutants also changed basal b-arrestin2 BiFC as shown in Figures 8 and 10.
*P < 0.05, ***P < 0.001 compared to values for the native Y receptor, using one-way ANOVA and Dunnett’s post test (Y1 mutations) or unpaired Student’s t-test (Y2
vs. Y2H155P).
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nature of the ligand which activates a single 7TMR (Hoffmann
et al., 2008). Although the Y1 receptor promotes sustained
endosomal recruitment of b-arrestin (Holliday et al., 2005),
the b-arrestin2 BiFC assay can equally be applied to the
b2-adrenoceptor which associates transiently with b-arrestin
at the plasma membrane (Oakley et al., 2000; Auld et al.,
2006; MacDonald et al., 2006; D. Lake and N. Holliday,
unpubl. obs.). However, the absence of BiFC dissociation is a
limitation for assessing how ligands stabilize 7TMR–b-arrestin
interaction, although more sustained complexes would
enhance the probability of Yn/Yc fragment refolding. Subse-
quent signalling and intracellular trafﬁcking of the stable
BiFC complex may also be atypical, for example, because the
ﬂuorescent 7TMR–b-arrestin fusion protein created by BiFC
impedes recycling (Oakley et al., 1999). This difference was
not obvious in our studies because both internalized Y1–YFP
receptors and Y1 receptor–b-arrestin2 BiFC complexes accu-
mulated in similar perinuclear compartments.
The Y1 receptor–b-arrestin2 BiFC assay demonstrated that
BIBP3226 and BIBO3304 were competitive antagonists, with
afﬁnity estimates consistent with those from other studies
(Michel et al., 1998; Wieland et al., 1998). GR231118 did not
stimulate Y1 receptor internalization, in contrast to a previous
report (Pheng et al., 2003), and it was an antagonist for Y1
receptor–b-arrestin2 interaction (as in other functional assays;
Michel et al., 1998). Steep GR231118 Schild plots may indi-
cate slow antagonist dissociation and conditions which do
not approach equilibrium (Christopoulos et al., 1999), rather
than an inherent behaviour of the BiFC assay. No antagonist
altered BiFC alone, but while this eliminates biased efﬁcacy
towards b-arrestin2 recruitment, it does not exclude possible
Figure 8 Mutating Y1 receptor C tail phosphorylation sites inhibits b-arrestin2 association. The upper diagram shows the C-terminal amino
acid sequence of the rat Y1 receptor, highlighting the region between positions 352 and 362, which contains six Ser/Thr residues (white text
on green) and which was identiﬁed previously as the key phosphorylated sequence in the receptor (Holliday et al., 2005). These Ser/Thr
residues were mutated individually or in combination, and eight stable Y1 mutant/barr2 cell lines established with closely matched expression
levels to Y1/barr2 cells (Table 2). NPY- and PYY-stimulated b-arrestin2 BiFC responses were measured for each mutant and normalized by
comparison with basal and 1 mM NPY Y1/barr2 control responses on the same plate. Each graph presents the pooled data (n = 4–5) with the
location of the Ala substitutions (white text on red) highlighted in the diagram above (STA = S352A, T353A; TSA = T361A, S362A; 5A = S352A,
T353A, S359A, T361A, S362A; 6A = S352A, T353A, T356A, S359A, T361A, S362A). In each case, the dotted curve represents the NPY
concentration–response curve for Y1/barr2 cells (as Figure 5B). The curve ﬁts yielded the pEC50 estimates in Table 3.
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arrestin2 cYFP complexes would be resistant to ligand-
induced dissociation. In principle, inverse agonists might
effect a change by preventing constitutive association of new
complexes, but this is unlikely to be detected with acute
incubations.
Recognition of agonist-occupied and phosphorylated
7TMRs requires distinct molecular determinants within
b-arrestins. First, the positive b-arrestin residues form new salt
bridges with phosphorylated or acidic residues in intracellular
7TMR domains. Disruption of the b-arrestin ‘polar core’ pro-
motes conformational rearrangement to a state more capable
of binding activated 7TMRs (Gurevich and Gurevich, 2006).
Within a previously identiﬁed phosphorylated region of the
Y1 receptor C tail (Holliday et al., 2005), sequential Ala sub-
stitution of the six Ser/Thr residues presents decreased
maximum b-arrestin2 binding without altering agonist
potency in the BiFC assay. This beﬁts mutations which affect
the phosphate ‘trigger’, rather than changing the discrimina-
tion by b-arrestin between empty and agonist-occupied recep-
tors. Surprisingly, the number of phosphorylation site
mutations (4/6 for substantive inhibition) proved to be more
important than their precise location. Thus, while one inhibi-
tory 4/6 mutant was equivalent to a previously reported criti-
cal binding motif (T356A, S359A, TSA; Ouedraogo et al.,
2008), a second set of 4/6 substitutions (STA, TSA) was equally
effective. Mutating the two remaining Ser/Thr was then nec-
essary to eliminate b-arrestin2 binding and internalization.
Both 5A and 6A mutants also reduced basal b-arrestin2 BiFC,
suggesting some constitutive Y1 receptor–b-arrestin2 interac-
tion, at least in transfected cells. This is consistent with some
basal Y1 receptor internalization identiﬁed by the live anti-
body labelling technique (Holliday et al., 2005), particularly
when b-arrestin2 is co-transfected (Figure 2).
The apparent redundancy in the exact phosphorylation
sites required for Y1 receptor–b-arrestin interaction concurs
with studies using rhodopsin (Doan et al., 2006) and chemok-
ine receptor 5 (Huttenrauch et al., 2002), although a more
complex interplay is also possible (Gurevich and Gurevich,
2006; Potter et al., 2006; Tobin et al., 2008). One implication
from the 4/6 mutants is that alternative arrangements of Y1
receptor phosphorylated residues can support some
b-arrestin2 interaction, consistent with a required cluster of
only two to three negative charges for b-arrestin binding
(Huttenrauch et al., 2002; Gurevich and Gurevich, 2006).
Intriguingly, this might confer distinct active b-arrestin con-
formations, as proposed recently (Tobin et al., 2008; Zidar
et al., 2009).
The second arrestin binding element recognizes activated
7TMRs, via less well-deﬁned receptor motifs (Huttenrauch
Figure 9 Phosphorylation site mutation prevents ligand and Y1
receptor internalization. 293TR Y1-GFP and Y16A-GFP cells (with all
six Ser/Thr substituted between Ser352 and S362) were treated with
tetracycline (1 mg·mL
-1) for 21 h to induce receptor expression. Con-
focal images were acquired from living cells before ligand addition, or
15 min after treatment with 1 mM NPY. Example images are repre-
sentative of three experiments.
Figure 10 Y2 receptor–b-arrestin2 interaction and its restoration by
H155P substitution. Concentration–response curves from pooled
analysis data (vesicle intensity/cell; n = 4–6 experiments) show
agonist-stimulated b-arrestin2 BiFC in stably transfected cells express-
ing Yc-tagged Y2 receptors (A) or the Y2H155P mutant (B). Both
Y2/b-arr2 and Y2H155P/b-arr2 cells expressed similar numbers of
receptors (Table 2), and Y2H155P/b-arr2 BiFC responses were nor-
malized with reference to Y2/b-arr2 controls in each experimental
plate. Dotted curves illustrate the positions of the Y1/b-arr2 (A) or
Y2/b-arr2 (B) NPY concentration–response curves for comparison.
ProNPY is [Leu
31, Pro
34]NPY.
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containing sequence following the DRY motif in intracellular
loop 2. Its restoration by H155P substitution in the Y2 recep-
tor increases b-arrestin interaction (Marion et al., 2006). Inter-
estingly, this mutant not only enhanced the size of the Y2
receptor–b-arrestin2 BiFC response, but signiﬁcantly
increased agonist potency, contrasting with potency-
independent actions of phosphorylation site mutants. Thus,
mutations which affect binding via the arrestin activation or
phosphorylation sensors display different characteristics in
the BiFC assay.
Various other approaches quantify recruitment of
b-arrestins to 7TMRs, each with its own advantages and pit-
falls. Other complementation methods include the restora-
tion of b-galactoside enzyme activity when 7TMRs and
b-arrestin associate (Carter and Hill, 2005). A second assay
(TANGO, Invitrogen; Hanson et al., 2009) requires the engi-
neered release of a transcription factor from the receptor on
b-arrestin binding, which then activates a downstream
b-lactamase reporter for assay. In both cases, detection is
straightforward in ﬁxed or lysed cells, but each requires addi-
tion of enzyme substrate, with no information on response
localization. The direct correspondence of BiFC with molecu-
lar 7TMR–b-arrestin interaction, and its applicability to living
cells, is best replicated by RET methods, or measurement of
b-arrestin–GFP translocation to unmodiﬁed 7TMRs (Hudson
et al., 2006). Here, the stability of the generated BiFC response
in living cells (in contrast to transient translocation or RET
responses) could actually offer a practical advantage for high-
content imaging purposes. All current b-arrestin assays,
including BiFC, share the limitation of their restriction to
recombinant cell systems, using transfected and modiﬁed
7TMR or b-arrestin proteins. Care must be taken in extrapo-
lating these results to the pharmacology and function of
native 7TMRs in their physiological context. For example, the
proﬁle and sites of 7TMR phosphorylation, which drives
b-arrestin recruitment, can differ signiﬁcantly between stan-
dard cell lines and native cells (Tobin et al., 2008). We have
shown that the 7TMR–b-arrestin2 assay can, in principle, be
performed in primary smooth muscle cells (N. Holliday,
unpubl. obs.); while this still requires recombinant proteins
and transfection, it should allow future investigations in a
more physiological cell environment.
The use of BiFC to study signalling is at an early stage, but
has signiﬁcant potential because of the simplicity and range
of measurements possible in living cells (MacDonald et al.,
2006; Kerppola, 2008; Rose et al., 2010). Here, we have shown
that this approach delivers robust quantitative pharmacology
focused on the molecular interaction between 7TMRs and
b-arrestin2. BiFC can be expanded in combination with BRET
(Gandia et al., 2008) or in multicolour assays (Mervine et al.,
2006) to examine co-operative or competitive multi-
component interactions. These present future opportunities
to put 7TMR–b-arrestin recruitment into the context of the
multi-protein signalling complexes it creates.
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37°C) before acquiring confocal BiFC ﬂuorescence and phase
images under identical settings.
Figure S2 Granularity algorithm to quantify Y1–YFP inter-
nalization. Automated plate reader images illustrate NPY-
(100 nM, 15 min) induced endocytosis of Y1 receptors
labelled with Y1vYFP (A). Below, granularity analysis identi-
ﬁes internalized receptors based on the same-sized vesicles as
for BiFC (3 mm + diameter, white dots), and H33342 stained
nuclei (not shown). Detection of plasma membrane Y1–YFP
ﬂuorescence was minimized because of the size and intensity
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